Longboard Pharmaceuticals Inc (NAS:LBPH)
$ 59.98 0.02 (0.03%) Market Cap: 2.34 Bil Enterprise Value: 2.06 Bil PE Ratio: 0 PB Ratio: 8.51 GF Score: 35/100

Longboard Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript

Sep 08, 2021 / 07:15PM GMT
Release Date Price: $10.45 (+0.97%)
Neena Bitritto;Garg
Citi Investment Research - Analyst

Good afternoon, everyone, and thank you for attending Citi's 16th Annual BioPharma Conference. I'm Neena Bitritto-Garg. I'm one of the biotech analysts here at Citi if you don't know me, and I'm pleased to be joined for our next fireside chat by Longboard Pharmaceuticals' management team, including CEO -- President and CEO, Kevin Lind; and Chief Medical Officer, Phil Perera. And today we're going to talk about the Company's CNS pipeline, including LP352, the Phase 1 data update that the Company released earlier this morning.

(Conference Instructions). And so just to start off, I'm actually going to pass it over to Kevin to make some opening remarks before getting into questions. Kevin?

Kevin Lind
Longboard Pharmaceuticals, Inc. - President & CEO

Thanks, Neena. Appreciate it. Just a reminder, we're going to be making forward-looking statements. Please refer to our SEC filings.

We are excited to be moving Longboard forward. We have three assets with best-in-class

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot